Drug
Sonidegib clinical trials
Also written LDE225, Odomzo and Erismodegib.
- studies test it
- 40
- open now
- 1
- in phase 3
- 0
- first study started
- 2009
Keep track of what changes. Save the sonidegib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
40 studies that test it; most in 2014 (12)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 6 |
| 2013 | 6 |
| 2014 | 12 |
| 2015 | 2 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 23
- Phase 2
- 16
- Phase 4
- 1
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 24
Novartis Pharmaceuticals (15) · Mayo Clinic (3) · Massachusetts General Hospital (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Anne Chang (2) · Gruppo Oncologico del Nord-Ovest (1) · University of Alabama at Birmingham (1) · Jemincare (1)
Often tested with
Tested in the same studies.
Gemcitabine (2) · Docetaxel (2) · Buparlisib (2) · Irinotecan (2) · Pembrolizumab (1) · Trametinib (1) · Filgrastim (1) · Lenalidomide (1)
Studies
Open first, then newest update. How each study uses sonidegib is read from its arms, and is right about nine times in ten.
Testing it · 40
- AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular CarcinomaRecruitingPhase 2University of FloridaNCT05669339Written as Sonidegib
- Tailored Sonidegib Schedule After Complete Response in BCCActive, not recruitingPhase 2Gruppo Oncologico del Nord-OvestNCT04806646Written as Sonidegib
- Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid TumorsActive, not recruitingPhase 1Mayo ClinicNCT04007744Written as Sonidegib
- Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian CancerCompletedPhase 1University of Alabama at BirminghamNCT02195973Written as LDE225
- Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed MedulloblastomaTerminatedPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT04402073Written as Sonidegib
- Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in ChinaCompletedPhase 4JemincareNCT06880848Written as Sonidegib Phosphate Capsules
- SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain TumorsCompletedPhase 1St. Jude Children's Research HospitalNCT03434262Written as sonidegib
- Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) PatientsCompletedPhase 1Spanish Breast Cancer Research GroupNCT02027376Written as LDE225
- Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedPhase 2Mayo ClinicNCT02086552Written as Sonidegib
- An East Asian Study of LDE225CompletedPhase 1Novartis PharmaceuticalsNCT01208831Written as LDE225
- Effect of Hepatic Impairment on LDE225..CompletedPhase 1Novartis PharmaceuticalsNCT01764776Written as LDE225
- Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid TumorsCompletedPhase 1Novartis PharmaceuticalsNCT01576666Written as LDE225
- Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in PatientsCompletedPhase 1Novartis PharmaceuticalsNCT01769768Written as LDE225
- Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid TumorsCompletedPhase 1Novartis PharmaceuticalsNCT00880308Written as LDE225
- Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer PatientsCompletedPhase 1Novartis PharmaceuticalsNCT01487785Written as LDE225+gemcitabine
- Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior TherapyCompletedPhase 1Novartis PharmaceuticalsNCT01456676Written as Nilotinib + LDE225
- LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic CancerCompletedPhase 1Massachusetts General HospitalNCT01485744Written as LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan
- LDE225 + Everolimus in Advanced Gastroesophageal AdenocarcinomaCompletedPhase 1M.D. Anderson Cancer CenterNCT02138929Written as LDE 225
- A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MFCompletedPhase 1/2Novartis PharmaceuticalsNCT01787552Written as LDE225
- Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic AdenocarcinomaTerminatedPhase 1/2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT01431794Written as LDE225-600mg
See all 40 studies that test sonidegib →
Given in every arm · 1 — sonidegib is usual care beside what is tested
As the comparator · 1 — what is tested is compared with sonidegib
Codes
What other systems call sonidegib · ClinicalTrials.gg INT005894
- MeSH (NLM) C561435sonidegibOne source NLM
- UNII (FDA) 0RLU3VTK5MSONIDEGIBConfirmed FDA, NLM, Wikidata
- RxNorm 1659191Confirmed FDA, Wikidata
- Wikidata Q22075856sonidegibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82385SonidegibOne source FDA
- DrugBank DB09143One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C561435 | sonidegib | One source NLM |
| UNII (FDA) | 0RLU3VTK5M | SONIDEGIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1659191 | — | Confirmed FDA, Wikidata |
| Wikidata | Q22075856 | sonidegib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82385 | Sonidegib | One source FDA |
| DrugBank | DB09143 | — | One source Wikidata |
Also registered as sonidegib phosphate (UNII W421AI34UW · RxNorm 1659192).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.